RxDoctor Payments Data

Michael Gaglia, MD

Interventional Cardiology · Pittsburgh, PANPI 1528031663

Payments from drug & device makers

$13,551in general payments, 2019–2025

Across 208 payments — averaging $65.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Chiesi USA, Inc.$4K
  • Medtronic$2K
  • Boston Scientific$952
  • Cardiovascular Systems Inc.$907
  • Stryker$656
  • Terumo Medical Corporation$542
  • plus $4K from 31 others

What the payments were for

  • Speaking & faculty fees$3,50026%
  • Travel & lodging$1,1699%
  • Food & beverage$8,86765%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,551 in reported general payments places this provider in the 55th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$97,952
Medicare patients
489
Services billed
1,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban255$222,389
EntrestoSacubitril/Valsartan116$96,852
JardianceEmpagliflozin66$60,645
XareltoRivaroxaban19$28,557
BrilintaTicagrelor34$27,648
FarxigaDapagliflozin Propanediol46$26,560
Repatha SureclickEvolocumab22$14,788
Atorvastatin Calcium284$2,381
Metoprolol Succinate148$2,079
ClopidogrelClopidogrel Bisulfate146$1,729
Ezetimibe60$1,665
Rosuvastatin Calcium90$1,326
Valsartan28$1,017
Losartan Potassium149$965
Carvedilol104$882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$140$222,389255 claims
NovartisEntresto$250$96,852116 claims
Boehringer IngelheimJardiance$88$60,64566 claims
AstraZenecaBrilinta, Farxiga$116$54,20880 claims
Johnson & JohnsonXarelto$294$28,55719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →